Literature DB >> 2019311

Cyclosporin A and its metabolites, distribution in blood and tissues.

H Akagi1, A Reynolds, M Hjelm.   

Abstract

Cyclosporin A (CsA), a non-myelotoxic immunosuppressant, and its metabolites are widely distributed in the body. Highest concentrations of CsA have been detected in the pancreas, adipose tissue and liver, lowest concentrations in brain, muscle, blood and other body fluids. Metabolites are distributed differently to CsA. In addition to lipid partition, intracellular binding to cyclophilin, a peptidyl-prolyl cis-trans isomerase, appears to play a role in its tissue distribution. The temperature dependence of such binding in erythrocytes poses difficulty in serum or plasma measurements. Tissue specific processes may also influence action and toxicity of CsA and its metabolites; thus, a better understanding of the complex distribution pattern of CsA and its metabolites would be important for establishing improved strategies and selection of appropriate specific methodologies for drug monitoring.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2019311     DOI: 10.1177/030006059101900101

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  5 in total

1.  Characterization of cyclosporine A uptake in human erythrocytes.

Authors:  C Reichel; M von Falkenhausen; D Brockmeier; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 2.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

4.  Chronopharmacokinetics of Cyclosporine A in the Wistar rat following oral administration.

Authors:  M F Malmary; K Kabbaj; C Labat; A Batalla; I Houti; S Moussamih; J Oustrin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

5.  Time-dependent inhibition of peptidylprolyl cis-trans-isomerases by FK506 is probably due to cis-trans isomerization of the inhibitor's imide bond.

Authors:  T Zarnt; K Lang; H Burtscher; G Fischer
Journal:  Biochem J       Date:  1995-01-01       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.